Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Citicoline for neurodevelopmental outcomes in preterm neonates with intraventricular hemorrhage
IRCT20171116037503N3Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of citicoline in Intraventricular hemorrhage (IVH) and neurodevelopmental delay (NDD) (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoint: Neurodevelopment of the infant. Started Oct 2024; status: completed.
02
Drugs
citicoline
03
Conditions
Intraventricular hemorrhage (IVH)neurodevelopmental delay (NDD)
Beyond the preview
Go deeper on IRCT20171116037503N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20171116037503N3.